Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate antigen sialyl-Lewis a is a tetrasaccharide glycan structure most commonly known as the serum tumor marker CA19‑9. It is composed of N-acetylneuraminic acid (sialic acid) α2–3 linked to galactose β1–3 linked to N-acetylglucosamine β1–R with an α1–4 fucose branch. This structure is typically found as the terminal modification on glycoproteins and glycolipids at the cell surface. Sialyl-Lewis a plays critical roles in cancer biology. It serves as an important ligand for E-selectin on vascular endothelium, facilitating adhesion of circulating cancer cells and promoting hematogenous metastasis. Its expression increases in malignant transformation due to altered glycosyltransferase activity during carcinogenesis; this makes it both a functional mediator of metastasis and an effective biomarker for diagnosis and monitoring of gastrointestinal cancers such as pancreatic, colorectal, and gastric tumors. In normal tissues, its more complex counterpart disialyl Lewis a predominates; loss of specific sialylation enzymes during early carcinogenesis leads to accumulation of monosialylated forms like sialyl-Lewis a in tumors. The ratio between monosialylated and disialylated forms can help distinguish malignant from benign conditions. Sialyl-Lewis antigens are part of the broader family known as tumor-associated carbohydrate antigens—glycan structures whose expression changes significantly in cancer cells compared to normal tissue. These molecules are under investigation as targets for immunotherapy approaches including vaccines and therapeutic antibodies due to their restricted expression patterns in malignancy. No approved drugs directly target this molecule itself; rather, it serves primarily as a diagnostic biomarker or potential immunotherapy target. There are no notable safety concerns associated with its use as a biomarker. For related structures such as sialyl-Lewis X (sLeX), similar biological functions apply—including roles in fertilization and immune cell trafficking—but these should not be conflated with sLea/CA19‑9 unless specifically indicated by context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbohydrate antigen sialyl-Lewis a (CA19-9).